floppy infant

(redirected from Peripheral nerve disease)

floppy infant

Floppy infant syndrome Neonatology A neonate with poor muscle tone and/or response to stimulation of extremities caused by a heterogeneous group of neuromuscular and musculoskeletal disorders
Floppy infant causes
Bone disease Osteogenesis imperfecta, rickets
CNS Atonic diplegia, cerebellar ataxia, cerebral lipidosis, chromosome defects, kernicterus, Lowe's oculocerebrorenal syndrome, Prader-Willi syndrome, Zellweger cerebrohepatocellular syndrome
Muscle disease Central core disease, glycogen storage disease type IIa–Pompe's disease, mitochondrial myopathies, muscular dystrophy, myotonic dystrophy, nemaline myopathy
Neuromuscular junction disease Botulism, myasthenia gravis
Peripheral nerve disease Amyotonia congenita, anterior horn cell disease, congenital sensory neuropathy, familial dysautonomia, Guillain-Barré syndrome, polyneuritis
Spinal cord disease Poliomyelitis, spinal cord trauma and tumors, transverse myelopathy, Werdnig-Hoffmann disease
Non-neuromuscular disease Endocrinopathies, metabolic disease, vitamin deficiency

flop·py in·fant

(flop'ē in'fănt)
A young child afflicted with neuromuscular or muscular disorders such that the limbs cannot move independently.
References in periodicals archive ?
Neurologists and other physicians caring for patients with peripheral nerve disease require increasingly sophisticated diagnostic and therapeutic tools.
As many as 95% of AIDS patients have evidence of peripheral nerve disease and about half of these individuals have neuropathic pain syndromes.
This clinically oriented diagnostic atlas features abundantly illustrated coverage of motor neuron and peripheral nerve diseases, myopathies and myasthenia, cerebral infarction and hemorrhage, dementia syndromes, extrapyramidal disorders, intracranial tumors, spinal tumors, developmental and familial disorders, pain syndromes & trauma, infections, multiple sclerosis, spinal disorders, cranial neuropathy, systemic disease, and epilepsy.
Aegera has in development two additional approaches to regulate apoptosis for cancer, and is also developing small molecule drugs to treat central and peripheral nerve diseases.
Peripheral nerve diseases including Bell's palsy and trigeminal nerve pain take 17.
Within the next 2-3 years, new studies are anticipated to begin with treatments for peripheral nerve diseases including pain and sensory neuropathy.
The Company's primary focus is developing small molecules that modulate signal transduction pathways to treat central and peripheral nerve diseases, and to restore normal cell-death mechanisms in cancer by inducing apoptosis (programmed cell death).
In addition to the Company's stem cell focus, Aegera is developing small molecule drugs to treat central and peripheral nerve diseases, and in cancer to restore normal cell-death mechanisms by inducing apoptosis.

Full browser ?